Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03146871 · OUTCOME

T-cell Subset Profile Assessed by Flow Cytometry

Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent · Source last updated 2026-06-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
At Baseline, then up to 2 years.

Analysis population: Not performed, study terminated early.

Groups in this outcome

Treatment (sEphB4-HSA, Azacitidine, Decitabine)

Patients receive recombinant EphB4-HSA fusion protein intravenously (IV) over 60 minutes on days 1 and 15. Patients also receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9, or decitabine IV on days 1-5. Administration of recombinant EphB4-HSA fusion protein occurs before or after the HMA (not concurrently). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Azacitidine: Given IV or SC Decitabine: Given IV Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Recombinant EphB4-HSA Fusion Protein: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (sEphB4-HSA, Azacitidine, Decitabine)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
groups
  1. description
    Patients receive recombinant EphB4-HSA fusion protein intravenously (IV) over 60 minutes on days 1 and 15. Patients also receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9, or decitabine IV on days 1-5. Administration of recombinant EphB4-HSA fusion protein occurs before or after the HMA (not concurrently). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Azacitidine: Given IV or SC Decitabine: Given IV Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Recombinant EphB4-HSA Fusion Protein: Given IV
    id
    OG000
    title
    Treatment (sEphB4-HSA, Azacitidine, Decitabine)
population Description
Not performed, study terminated early.
reporting Status
POSTED
time Frame
At Baseline, then up to 2 years.
title
T-cell Subset Profile Assessed by Flow Cytometry
type
OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice